retatrutide weight loss trial retatrutide Severe Obesity Shows 30% Lilly's triple agonist delivers up

In February of 2025, the FDA declared a shortage of GLP-1 semaglutide, the active ingredient in Ozempic and Wegovy

But here's the challenge: GLP-1 medications dramatically reduce appetite and portion tolerance

#GLP1 #Noom #ObesityTreatment #DigitalHealth #WeightLoss #Semaglutide #HealthTech #CompoundedDrugs #PharmaInnovation #BehavioralHealth Noom launches Microdose GLP-1Rx Program for affordable weight loss Noom has launched its Microdose GLP-1Rx Program to improve affordability and reduce side effects tied to weight loss medications

CryoEM and model parameters Table S2: Interactions between the GLP-1R and GLP-1, PF-06882961 or OWL833 Figure S1

This might include modifying doses, changing administration timing, or adding complementary treatments